SION Sionna Therapeutics Inc

Sionna Therapeutics announced a major strategic restructuring that includes a 46% workforce reduction and a renewed focus on its dual SION-451 + SION-2222 combination. The company plans to advance the therapy into the Phase 2a AscenSION CF proof-of-concept study, expected to begin in the first quarter of 2027. At the same time, Sionna will discontinue SION-719 as an add-on therapy after the Phase 2a PreciSION CF trial failed to meet its primary endpoint for reducing sweat chloride. The workforce reduction is expected to generate about $6.4 million in restructuring charges, while cost-cutting measures are projected to extend the company’s cash runway into the second half of 2029. Sionna ended the second quarter with approximately $268 million in cash. Investor sentiment was further pressured by Raymond James, which downgraded the stock to Market Perform from Strong Buy, following a series of analyst downgrades after the August 10 clinical setback. $SION